MTND4LP17

Across TCGA pan-cancer cohorts, MTND4LP17 RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated MTND4LP17 data layer.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher MTND4LP17 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTND4LP17 expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

UCS, GBM, and STAD are the cancer types where MTND4LP17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Tertile	III,IV	0.104	0.591	.004	72	view →
GBM	OS	Tertile	All	0.076	0.415	<.001	36	view →
STAD	OS	Tertile	III,IV	0.507	0.657	.033	24	view →
ESCA	OS	Quartile	III,IV	0.721	0.349	.025	15	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MTND4LP17–UCS (OS)

Open the UCS breakdown →